Close Menu

Cancer

The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing.

During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.

The company doesn’t expect significant revenue from the test this year, but executives said that they are already seeing positive reception trends.

The genomics company reported revenues of $20.2 million for the quarter, driven by growth in its pharmaceutical services business and other non-VA customers.

The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.

The firm posted total software-related revenues of $18.6 million, up 1 percent from $18.4 million in Q4 2019.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
17
Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
23
Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
24
Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.